Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55.6M
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
1.78M
-
Shares change
-
+1.41M
-
Total reported value, excl. options
-
$342K
-
Value change
-
+$268K
-
Number of buys
-
10
-
Number of sells
-
-8
-
Price
-
$0.19
Significant Holders of Processa Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PCSA) as of Q3 2025
19 filings reported holding PCSA - Processa Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2025.
Processa Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PCSA) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.78M shares
of 55.6M outstanding shares and own 3.21% of the company stock.
Largest 10 shareholders include Stonepine Capital Management, LLC (1.03M shares), GEODE CAPITAL MANAGEMENT, LLC (303K shares), VANGUARD GROUP INC (288K shares), Virtu Financial LLC (40.8K shares), TWO SIGMA SECURITIES, LLC (36.2K shares), CITIGROUP INC (34.1K shares), StoneX Group Inc. (19K shares), Sassicaia Capital Advisers LLC (16K shares), Miracle Mile Advisors, LLC (10K shares), and Tower Research Capital LLC (TRC) (2.39K shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.